In the US, Lenvima (lenvatinib systemic) is a member of the following drug classes: multikinase inhibitors, VEGF/VEGFR inhibitors and is used to treat Hepatocellular Carcinoma, Renal Cell Carcinoma and Thyroid Cancer.
Ingredient matches for Lenvima
Lenvatinib mesylate (a derivative of Lenvatinib) is reported as an ingredient of Lenvima in the following countries:
- United Kingdom
- United States
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.